Key facts for Q2043
- Billing unit
- Per infusion (minimum 50 million cells)
- Sipuleucel-t auto cd54+
- ASP payment limit
- $55,663.131
- October 2026; -0.5% vs July 2026
- Practitioner MUE
- 1
- MAI 2
- NCCI exposure
- 1 col-2 pairs
- 100% allow a modifier
- Coverage articles
- 1
- 6 states
TL;DR
HCPCS Q2043 is the Level II code for Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion, billed per Per infusion (minimum 50 million cells). The Medicare Part B ASP payment limit for October 2026 is $55,663.131 per billing unit, down 0.5% from July 2026. The practitioner MUE allows up to 1 units per date of service (MAI 2), so a full 1-unit day is $55,663.13 at the current limit. Under OPPS it carries status indicator K in APC 9273. Q2043 is billed in units of Per infusion (minimum 50 million cells); the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 1 NDC to it, sold as Provenge by Dendreon Pharmaceuticals LLC. It is the bundled column-2 code in 1 NCCI pair, most often with 36522. 1 Medicare coverage article lists the code across 6 states, including A55719.
Medicare Part B payment limit (ASP)
CMS sets the Part B payment limit for Q2043 at $55,663.131 per Per infusion (minimum 50 million cells) for October 2026, derived from manufacturer average sales price plus 6%, compared with $55,932.427 in July 2026. Beneficiary coinsurance is 20%.
| Quarter | Payment limit | Per | Coinsurance |
|---|---|---|---|
| October 2026 | $55,663.131 | Per infusion (minimum 50 million cells) | 20% |
| July 2026 | $55,932.427 | Per infusion (minimum 50 million cells) | — |
NDC to HCPCS billing-unit conversion
The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to Q2043. Report the NDC in the claim's drug segment and bill the number of Q2043 units that equals the quantity administered divided by Per infusion (minimum 50 million cells); the last column gives units per full package.
| NDC | Drug name | Labeler | Package size | Billing units / package |
|---|---|---|---|---|
| 30237-8900-06 | Provenge | Dendreon Pharmaceuticals LLC | 250 × 1 | 1 |
Medically Unlikely Edits (MUE)
CMS publishes 2 MUE values for Q2043. For practitioners the limit is 1 unit per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.
| Setting | MUE (units/DOS) | MAI | CMS rationale |
|---|---|---|---|
| Practitioner services | 1 | 2 Date of Service Edit: Policy | Code Descriptor / CPT Instruction |
| Facility outpatient hospital | 1 | 2 Date of Service Edit: Policy | Code Descriptor / CPT Instruction |
MUE for Q2043 in every setting opens the lookup with this code filled in, next to any other code on the same claim.
NCCI edits and add-on relationships
In the practitioner PTP file v323r0 (effective October 1, 2026), Q2043 is the column-2 code in 1 active pair, 100% of which allow a modifier (indicator 1), and the column-1 code in 171. 113 historical pairs have been deleted over time. CMS's most frequent rationale: Mutually exclusive procedures.
When billed with these column-1 codes, Q2043 is the bundled component unless the pair allows a modifier and the documentation supports a distinct service.
| Column-1 code | Pairs |
|---|---|
| 36522 (CPT; descriptor licensed by AMA) | 1 |
These codes are considered components of Q2043 when reported together on the same date of service.
| Column-2 code | Pairs |
|---|---|
| 0213T (CPT; descriptor licensed by AMA) | 1 |
| 0216T (CPT; descriptor licensed by AMA) | 1 |
| 0596T (CPT; descriptor licensed by AMA) | 1 |
| 0597T (CPT; descriptor licensed by AMA) | 1 |
| 0692T (CPT; descriptor licensed by AMA) | 1 |
| 0903T (CPT; descriptor licensed by AMA) | 1 |
| 0904T (CPT; descriptor licensed by AMA) | 1 |
| 0905T (CPT; descriptor licensed by AMA) | 1 |
| 36000 (CPT; descriptor licensed by AMA) | 1 |
| 36400 (CPT; descriptor licensed by AMA) | 1 |
The counts above are exposure, not answers for a specific claim. Check Q2043 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.
Q2043 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.
Medicare coverage articles
1 current Medicare Administrative Contractor article lists Q2043 in their HCPCS tables, covering 6 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.
| Article | Title | Contractor(s) | States | Related LCD |
|---|---|---|---|---|
| A55719 | Sipuleucel-T (Provenge®) - Coverage Criteria for Prostate Cancer – Clarification | Noridian Healthcare Solutions, LLC | AZ MT ND SD UT WY | — |
Diagnoses Medicare contractors cover for Q2043
One billing and coding article attaches a covered diagnosis list to Q2043: 23 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).
| ICD-10-CM | Description (FY2027) | Articles covering |
|---|---|---|
| C61 | Malignant neoplasm of prostate | 1 of 1 |
| C77.1 | Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes | 1 of 1 |
| C77.2 | Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes | 1 of 1 |
| C77.4 | Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes | 1 of 1 |
| C77.5 | Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes | 1 of 1 |
| C77.8 | Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions | 1 of 1 |
| C77.9 | Secondary and unspecified malignant neoplasm of lymph node, unspecified | 1 of 1 |
| C78.00 | Secondary malignant neoplasm of unspecified lung | 1 of 1 |
| C78.01 | Secondary malignant neoplasm of right lung | 1 of 1 |
| C78.02 | Secondary malignant neoplasm of left lung | 1 of 1 |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct | 1 of 1 |
| C79.00 | Secondary malignant neoplasm of unspecified kidney and renal pelvis | 1 of 1 |
| C79.01 | Secondary malignant neoplasm of right kidney and renal pelvis | 1 of 1 |
| C79.02 | Secondary malignant neoplasm of left kidney and renal pelvis | 1 of 1 |
| C79.10 | Secondary malignant neoplasm of unspecified urinary organs | 1 of 1 |
Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q2043 are counted here. The full list opens on the policy page with every group, the non-covered codes and the instructions.
| Article | Contractor | Groups that apply | Covered codes for Q2043 | Full list |
|---|---|---|---|---|
| A55719 | Noridian Healthcare Solutions, LLC | one list for every code in the article | 23 | Open the list |
Hospital outpatient (OPPS) status
In the October 2026 OPPS Addendum B, Q2043 carries status indicator K and is assigned to APC 9273, with a published national unadjusted payment of $55,663.131. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.
Ambulatory surgical center (ASC) payment
In the October 2026 ASC Addendum BB (covered ancillary services), Q2043 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $55,663.13 per Per infusion (minimum 50 million cells), paid only when the drug is furnished integral to a covered surgical procedure.
Common denials for Q2043 and how to prevent them
For teams evaluating QuickIntell software
Evaluate a coding workflow for Q2043
Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
In QuickIntell research
- 2026 Q4 most-bundled codes report: Q2043 is the column-2 code in 1 active practitioner NCCI pairs, one of 12 Part B drug codes that NCCI bundles at all.
- J codes by drug name: Every code for the same drug, generic or brand, in one A-Z index.
Frequently asked questions — HCPCS Q2043
What does HCPCS code Q2043 describe?
Q2043 is defined by CMS as "Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion". Each billing unit represents Per infusion (minimum 50 million cells), so the units reported on the claim must equal the dose administered divided by that unit.
Is Q2043 a CPT code?
No. Q2043 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as sipuleucel-t (Provenge); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q2043 reports the drug itself in per infusion (minimum 50 million cells) units, and the administration is billed on its own line.
What is the Medicare reimbursement for Q2043 in October 2026?
The ASP-based payment limit is $55,663.131 per Per infusion (minimum 50 million cells), with 20% beneficiary coinsurance. The July 2026 limit was $55,932.427. Commercial payers use their own fee schedules.
How many units of Q2043 can be billed per day?
The practitioner Medically Unlikely Edit is 1 units per date of service with adjudication indicator 2 (Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Code Descriptor / CPT Instruction" as the rationale.
Which NDCs map to Q2043?
The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Provenge (Dendreon Pharmaceuticals LLC). For example NDC 30237-8900-06 (package size 250) equals 1 billing unit of Q2043.
Does Q2043 have NCCI bundling edits?
In the v323r0 practitioner PTP file, Q2043 appears as the column-2 (bundled) code in 1 active pairs and as the column-1 code in 171. 100% of the column-2 pairs allow a modifier (indicator 1). The most frequent column-1 partners are 36522, and CMS's leading rationale is "Mutually exclusive procedures".
Which Medicare coverage articles mention Q2043?
1 current Billing and Coding Article in the Medicare Coverage Database lists Q2043, covering 6 states: A55719 (Sipuleucel-T (Provenge®) - Coverage Criteria for Prostate Cancer – Clarification).
What diagnosis codes support Q2043?
One Medicare billing and coding article lists 23 covered ICD-10-CM codes for Q2043, for example C61 (Malignant neoplasm of prostate); C77.1 (Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes); C77.2 (Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes); C77.4 (Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes); C77.5 (Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- Medicare Part B Drug Payment Limit File, July 2026Version July 2026 · effective 2026-07-01 · file section 508 version of July 2026 Medicare Part B Payment Limit File updated 082026.csvSHA-256 13bb5b644b92b574…
- ASP NDC-HCPCS Crosswalk, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 ASP NDC-HCPCS Crosswalk 091126.csvSHA-256 5cb78f0c2ee786ba…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI MUE table, facility services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_OutpatientHospitalServices_Eff_10-01-2026.csvSHA-256 3af9f4e99cc587e2…
- NCCI MUE table, dme services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_DMESupplierServices_Eff_10-01-2026.csvSHA-256 6fa4fbba852f7b74…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- NCCI Add-On Code edits, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file AOC_V2026Q4-F-MCR.xlsxSHA-256 eabb519623134549…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
- ASC Addendum BB (covered ancillary services), October 2026Version October 2026 · effective 2026-10-01 · file Oct 2026 ASC BB.txtSHA-256 63cdd7c72aba7a25…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.